Spirit Airlines (OTC:FLYYQ) is preparing for a potential shutdown after a proposed financial rescue package failed to come together, according to a Wall Street Journal report citing people with knowledge of the matter.
The ultra-low-cost carrier had been seeking roughly $500 million in emergency funding intended to stabilize its finances and keep operations running.
Estee Lauder Companies Inc (NYSE:EL, XETRA:ELAA) posted stronger-than-expected third-quarter results on Friday, raising its full-year outlook while announcing an expansion of its workforce reduction program to as many as 10,000 positions.
The beauty conglomerate reported revenue of $3.71 billion for the quarter ended March 2026, edging past analyst estimates of $3.69 billion. Adjusted earnings per share came in at $0.91, well above the $0.65 consensus estimate.
Atlassian (NASDAQ:TEAM) shares jumped about 23% on Friday morning following stronger-than-expected fiscal third quarter results and an upward revision to its full-year revenue outlook.
For fiscal 2026, the company raised its total revenue growth forecast to approximately 24%, up from a prior outlook of 22%. It continues to expect cloud revenue growth of about 26.5% and non-GAAP operating margin of roughly 29%.
Replenish Nutrients Holding Corp (CSE:ERTH, OTC:VVIVF, FRA:7KE) has reported its fourth-quarter and full-year 2025 financial results, highlighting progress in scaling its regenerative fertilizer platform alongside continued net losses as the company transitions toward commercialization.
For the fourth quarter ended December 31, 2025, revenue rose to $3 million from $2.6 million a year earlier, driven by higher fertilizer sales volumes and pricing.
Reddit Inc (NYSE:RDDT) reported stronger-than-expected first-quarter results on Friday, with revenue surging past Wall Street estimates as the social media platform continued to gain traction with advertisers adopting its lower-funnel advertising products.
The company posted revenue of $663 million, topping analyst estimates of $611 million, while adjusted earnings per share came in at $1.01, well ahead of the $0.58 expected.
Roblox Corp (NYSE:RBLX) shares fell 19% after the company reported first-quarter results that missed expectations on revenue, bookings and daily active users, while also cutting its forward guidance.
Revenue came in at approximately $1.4 billion to $1.44 billion, missing consensus estimates of $1.74 billion.
Rivian Automotive Inc (NASDAQ:RIVN) reported first-quarter 2026 results that topped analyst estimates across key metrics, as the electric vehicle maker kicked off scalable production of its long-awaited R2 model and expanded capacity at its Georgia manufacturing facility.
Revenue for the quarter ended March 31 came in at $1.38 billion, up 11% year-over-year and ahead of the consensus estimate of $1.36 billion, driven by a 20% increase in delivery volumes and a surge in software and services revenue.
Sandisk (NASDAQ:SNDK) reported fiscal third quarter results that surpassed Wall Street expectations on both revenue and earnings, as demand tied to AI-driven data center growth boosted performance.
The company posted adjusted earnings per share of $23.41, well above estimates of $14.66, while revenue reached $5.95 billion, exceeding expectations of $4.73 billion. Revenue rose 97% sequentially and 251% year over year.
Apple Inc (NASDAQ:AAPL) shares rose 2.75% in after-hours trading after the iPhone maker group reported quarterly results ahead of market expectations.
Revenue came in at $111.18 billion for the March quarter, up 17%, beating forecasts of $109.46 billion. Earnings per share of $2.01 also came in ahead of estimates.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a key breast cancer setting.
The FTSE 100 drugmaker said the Oncologic Drugs Advisory Committee of the Food and Drug Administration (FDA) voted three to six against the benefit-risk profile of camizestrant in combination with a CDK4/6 inhibitor for first-line treatment of advanced hormone receptor-positive breast cancer.
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market and announced the departure of its finance chief.
The pharmaceutical company, which focuses on iron deficiency treatments, said group net revenues rose to $18 million in the quarter, up from $7 million a year earlier, with EBIT of about $2.5 million compared to a $4.4 million loss previously.